Radiation Oncology/Therapy

Accuray to restructure debt, forge partnerships in turnaround plan

By AuntMinnie.com staff writers

Planned partners include Samsung HME America's NeuroLogica division and RaySearch Laboratories.

July 30, 2026

Ablative RT shows promise in treating pancreatic cancer

By Amerigo Allegretto

Ablative radiotherapy led to promising survival outcomes in patients with locally advanced pancreatic cancer.

July 29, 2026

Fuse Oncology launches FuseRx prescribing platform

By AuntMinnie.com staff writers

FuseRx enables physicians to build a structured treatment intent plan.

July 20, 2026

Actineer completes Ra-226 recycling process to support Ac-225 supply

By AuntMinnie.com staff writers

This process aims to improve Ac-225 supply predictability and cost stability, as well as reduce waste generation.

July 14, 2026

ASTRO urges Congress to address radiation oncology payment crisis

By AuntMinnie.com staff writers

This action comes in the wake of recent analyses pointing toward reimbursement declines and disappearing radiation oncology clinics.

July 14, 2026

ASTRO highlights study on disappearing radiation oncology centers

By Amerigo Allegretto

Over two-thirds of all U.S. counties reported lacking a radiation oncology practice site in 2025.

July 10, 2026

PreludeDx, Learn Look Locate launch DCIS patient education resource

By AuntMinnie.com staff writers

The patient-centered guide will cover various aspects of DCIS, including recurrence risk and radiation therapy decision-making.

July 9, 2026

Blue Earth, UCL dose first patient in Ac-225 PSMA prostate trial

By AuntMinnie.com staff writers

The study is evaluating an investigational alpha-emitting PSMA-targeted radiopharmaceutical in prostate cancer patients.

July 9, 2026

Leo Cancer Care nets $65M to deploy proton therapy system

By AuntMinnie.com staff writers

Stanford Medicine used the system to treat a pediatric brain tumor patient on June 4.

July 8, 2026

Radnostix acquires Lara System, Ellexa software from Lucerno

By AuntMinnie.com staff writers

The acquisitions also include associated intellectual property for monitoring radiopharmaceutical administration.

July 2, 2026

Nearly half of mCRPC patients never receive second-line treatment

By Will Morton

ARPIs were the most common first-line treatment (79.3%) and remained the most common second-line treatment (41.1%).

June 29, 2026

Canadian alliance issues white paper for AI in radiation therapy

By Amerigo Allegretto

CADRA has issued a white paper calling for collaboration, education, and oversight for AI in radiation therapy.

June 25, 2026

Page 1 of 472

Next Page